Mandatory national virtual tumour boards for rare and complex cancers
A patient with a rare cancer treated at a small hospital should have their case reviewed by the national experts by video before treatment starts. Make that referral automatic.
Outcomes for sarcoma, rare gynaecological tumours, and other uncommon cancers depend heavily on expert review before surgery, yet many patients are treated locally without it. National virtual multidisciplinary boards, with mandatory pre-treatment referral for a defined list of diagnoses and a turnaround guarantee, have been implemented for sarcoma in several countries. Extending the model with a legal or reimbursement mandate would standardise access.
- Fragmented care and guideline gaps · Patients fall between specialists, wait for referrals and often do not get the treatment guidelines say they should.
- Rare and paediatric cancers without markets · Taken together rare cancers are a fifth of all cancers, but each one alone is too small for a company to invest in.
Pages like this
not linked directly; found by shared links- IdeaA funded expert second opinion for every new high-stakes or rare cancer diagnosis
Shares Neuroendocrine tumours, Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- CompanySpringWorks Therapeutics (Merck KGaA)
Shares Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- IdeaOne legal framework for pooling rare cancer data across borders
Shares Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- IdeaTrial-in-a-box: a preconfigured protocol kit any hospital can open for a rare cancer
Shares Neuroendocrine tumours, Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- IdeaOne global rare cancer network with n-of-1 and Bayesian trial frameworks
Shares Neuroendocrine tumours, Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- IdeaLet adolescents from age 12 into adult trials when the cancer biology is the same
Shares Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- IdeaA digital second-opinion network answering community oncologists within 72 hours
Shares Fragmented care and guideline gaps, Rare and paediatric cancers without markets.
- IdeaThe pathology lab triggers a trial referral the day a rare cancer is diagnosed
Shares Neuroendocrine tumours, Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).